Atrial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke

Clinical Trial

Study Status:

Contact Information:

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose

The primary aim of this study is to test that apixaban is superior to aspirin for the prevention of recurrent stroke in subjects with cryptogenic ischemic stroke and atrial cardiopathy. Another ais is to test that the relative efficacy of apixaban over aspirin increases with the severity of atrial cardiopathy.

Information

Principal Investigator	Wady Aude, MD
Co-PI
Sponsor	National Institute of Neurological Disorders and Stroke
Type of Trial	Prospective

Ask

We are here to help. If you have any question about your participation in a clinical trial, please contact us.

Participate

To participate in existing clinical trials, please contact us